Alkem Laboratories Limited (NSE: ALKEM) has announced the launch of Renocia Exo™, India’s first patented Ginsenoside exosome-based hair growth serum. This innovative product aims to address hair loss through a comprehensive scientific approach. Unlike conventional treatments, Renocia Exo™ focuses on supporting the biology of the hair follicle by integrating Ginsenoside phyto-exosomes, biomimetic peptides, copper peptides, and stem cell-supportive actives.

Innovative Approach to Hair Loss Management

Hair loss has become a significant concern in India, affecting both aging adults and younger individuals due to genetics, lifestyle changes, and environmental stressors. Alkem’s new product, Renocia Exo™, is developed to support the health and vitality of the hair follicle through multiple regenerative technologies. The formulation supports several interconnected biological processes associated with healthy hair follicle function, promoting a favorable environment for stronger, healthier hair over time.

Comprehensive Scientific Formulation

Renocia Exo™ is designed to support multiple signaling pathways involved in hair follicle activity. Its lightweight, cosmetically elegant composition is free from alcohol, sulphates, silicones, parabens, and mineral oil, making it suitable for regular use as part of dermatologist-guided hair loss management. The product’s innovative approach marks a significant step forward in the science of hair restoration, addressing the complex interplay of biological mechanisms that drive hair thinning.

With the launch of Renocia Exo™, Alkem continues to strengthen its dermatology portfolio by translating emerging scientific insights into practical therapeutic innovations that address evolving patient needs. This launch underscores Alkem’s commitment to inspiring healthier lives through advanced scientific research and development.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Alkem Laboratories Limited

Alkem Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Alkem trades in the lower quarter of its 52-week range. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The PEG of 0.89 signals undervaluation relative to growth. It is a potential re-rating candidate. The stock sits at 20% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 8.3% and profits at 32.7%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Alkem Laboratories Limited.

Alkem Laboratories Limited (NSE: ALKEM) today announced its standalone and consolidated financial results for the first quarter ended June 30, 2026. The Board of Directors took record of these results at its meeting held in Mumbai today. Commenting on the results, Mr. Sandeep Singh, MD of Alkem, said, “We have started FY27 on a steady note, with healthy growth across our India and international businesses. Our India business continued to outperform the market, while the strong growth in our non-US international markets was encouraging. However, there are areas where we need to improve, particularly in strengthening execution, addressing operational and regulatory priorities, and improving the consistency of performance across our businesses. We are also investing in R&D, MedTech and Biotech as we build our next phase of growth. Our focus will be to strengthen the core, address the areas that need improvement and build these newer opportunities in a disciplined manner.”

Q1 FY27 Key Financial Highlights

• Total Revenue from Operations was ₹37,402 million, with YoY growth of 10.9%. o India sales were ₹24,978 million, YoY growth of 10.3%. o International sales were ₹12,223 million, with YoY growth of 16.0%.

Operational Highlights

Domestic Business Key Highlights: The contribution of domestic sales to total sales was 67.1% vs. 68.2% in Q1 FY26. According to IQVIA (SSA) data, for Q1 FY27: o The Company registered a growth of 13.2% YoY vs Indian Pharmaceutical Market (IPM), which grew by 12.2 %, 100 bps outperformance.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Alkem Laboratories Limited

Alkem Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Alkem moves sideways over three months, with neither buyers nor sellers taking control. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The PEG of 0.87 signals undervaluation relative to growth. It is a potential re-rating candidate. Buyers show up with 1.5x the volume of sellers. Moreover, they dominated on 17 of recent sessions versus 13 for sellers — a healthy accumulation pattern. Revenue grows at 8.3% and profits at 32.7%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Alkem Laboratories Limited.

Alkem Laboratories Limited (NSE: ALKEM) has made a significant stride in the pharmaceutical sector by becoming the first company in India to launch semaglutide in single-shot pre-filled syringes, starting at an affordable price of INR 350. This move aims to lower entry barriers to semaglutide treatment for patients, expanding treatment options and enhancing access. The ready-to-use single-shot pre-filled syringe format offers convenience and is an important step in helping more patients start and stay on the therapy. The company has received approval from the Drugs Controller General of India (DCGI) to manufacture and market these pre-filled syringes for the management of Type 2 diabetes mellitus and obesity as an adjunct to diet and exercise.

Expanding Treatment Options

In March 2026, Alkem had already launched semaglutide in pre-filled disposable and reusable injection pens format in the Indian market. The company has also received regulatory approval for semaglutide vials, which will be launched soon. Dr. Vikas Gupta, Chief Executive Officer, Alkem, commented on this development, stating, “Semaglutide has the potential to change how we manage metabolic disorders. With the launch of our pre-filled syringes, we are widening the choice available to doctors and patients, alongside the pen options we have already introduced.”

Commitment to Affordable Medicines

Alkem Laboratories Limited remains committed to advancing high-quality, affordable medicines across key therapeutic areas and supporting better patient care in India. With 18 state-of-the-art manufacturing facilities and cutting-edge research and development centers across India and the US, Alkem continues to focus on developing and manufacturing generic formulations, active pharmaceutical ingredients (APIs), and biosimilars. The company’s mission to ‘Inspire Healthier Lives’ underscores its dedication to global health improvement.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Alkem Laboratories Limited

Alkem Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Alkem moves sideways over three months, with neither buyers nor sellers taking control. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The PEG of 0.84 signals undervaluation relative to growth. It is a potential re-rating candidate. The stock holds at 49% of its 52-week range with RSI at 42. In other words, neither side has a clear edge right now. Revenue grows at 8.7% and profits at 32.7%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Alkem Laboratories Limited.